ALLO – Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc.ALLO
$1.35Name : Allogene Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $299,539,392.00
EPSttm : -1.1
Allogene Therapeutics, Inc.
$1.35
2.17%$0.03Float Short %
13.26
Margin Of Safety %
Put/Call OI Ratio
0.14
EPS Next Q Diff
0.02
EPS Last/This Y
0.3
EPS This/Next Y
0.04
Price
1.34
Target Price
7.51
Analyst Recom
1.54
Performance Q
11.57
Relative Volume
0.59
Beta
0.41
Ticker: ALLO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | ALLO | 1.135 | 0.53 | 0.24 | 4626 |
| 2025-09-09 | ALLO | 1.135 | 0.53 | 2.00 | 4664 |
| 2025-09-10 | ALLO | 1.12 | 0.53 | 0.10 | 4676 |
| 2025-09-11 | ALLO | 1.165 | 0.52 | 2.31 | 4768 |
| 2025-09-12 | ALLO | 1.125 | 0.59 | 0.52 | 5104 |
| 2025-09-15 | ALLO | 1.135 | 0.59 | 0.38 | 5161 |
| 2025-09-16 | ALLO | 1.175 | 0.59 | 0.17 | 5187 |
| 2025-09-17 | ALLO | 1.13 | 0.58599695585997 | 7.1739130434783 | 5210 |
| 2025-09-18 | ALLO | 1.2 | 0.59 | 0.99 | 5259 |
| 2025-09-19 | ALLO | 1.14 | 0.60 | 0.27 | 5196 |
| 2025-09-22 | ALLO | 1.17 | 0.15 | 1.48 | 3243 |
| 2025-09-23 | ALLO | 1.16 | 0.19 | 0.40 | 3420 |
| 2025-09-24 | ALLO | 1.225 | 0.18 | 0.14 | 3488 |
| 2025-09-25 | ALLO | 1.2 | 0.18 | 0.15 | 3674 |
| 2025-09-26 | ALLO | 1.245 | 0.17 | 0.44 | 3802 |
| 2025-09-29 | ALLO | 1.265 | 0.17 | 0.54 | 3809 |
| 2025-09-30 | ALLO | 1.235 | 0.16 | 1.39 | 3788 |
| 2025-10-01 | ALLO | 1.25 | 0.15 | 0.00 | 3776 |
| 2025-10-02 | ALLO | 1.285 | 0.15 | 0.06 | 3807 |
| 2025-10-03 | ALLO | 1.335 | 0.15 | 0.00 | 3732 |
| 2025-10-06 | ALLO | 1.385 | 0.15 | 0.03 | 3776 |
| 2025-10-07 | ALLO | 1.345 | 0.14 | 0.02 | 3840 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | ALLO | 1.14 | 12.9 | - | -1.02 |
| 2025-09-09 | ALLO | 1.13 | 12.9 | - | -1.02 |
| 2025-09-10 | ALLO | 1.12 | 12.9 | - | -1.02 |
| 2025-09-11 | ALLO | 1.17 | 12.9 | - | -1.02 |
| 2025-09-12 | ALLO | 1.12 | 12.9 | - | -1.02 |
| 2025-09-15 | ALLO | 1.15 | 12.9 | - | -1.02 |
| 2025-09-16 | ALLO | 1.18 | 12.9 | - | -1.02 |
| 2025-09-17 | ALLO | 1.13 | 12.9 | - | -1.02 |
| 2025-09-18 | ALLO | 1.21 | 12.9 | - | -1.02 |
| 2025-09-19 | ALLO | 1.15 | 12.9 | - | -1.02 |
| 2025-09-22 | ALLO | 1.17 | 12.9 | - | -1.02 |
| 2025-09-23 | ALLO | 1.16 | 12.9 | - | -1.02 |
| 2025-09-24 | ALLO | 1.22 | 12.9 | - | -1.02 |
| 2025-09-25 | ALLO | 1.20 | 12.9 | - | -1.02 |
| 2025-09-26 | ALLO | 1.25 | 12.9 | - | -1.02 |
| 2025-09-29 | ALLO | 1.26 | 12.9 | - | -1.02 |
| 2025-09-30 | ALLO | 1.24 | 12.9 | - | -1.02 |
| 2025-10-01 | ALLO | 1.25 | 12.9 | - | -1.02 |
| 2025-10-02 | ALLO | 1.28 | 12.9 | - | -1.02 |
| 2025-10-03 | ALLO | 1.34 | 12.9 | - | -1.02 |
| 2025-10-06 | ALLO | 1.38 | 12.9 | - | -1.02 |
| 2025-10-07 | ALLO | 1.34 | 12.9 | - | -1.02 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | ALLO | -0.14 | -6.57 | 16.10 |
| 2025-09-09 | ALLO | -0.14 | -6.57 | 16.10 |
| 2025-09-10 | ALLO | -0.14 | -6.57 | 16.10 |
| 2025-09-11 | ALLO | -0.14 | -6.57 | 13.04 |
| 2025-09-12 | ALLO | -0.14 | -6.57 | 13.04 |
| 2025-09-15 | ALLO | -0.14 | -6.53 | 13.04 |
| 2025-09-16 | ALLO | -0.14 | -6.53 | 13.04 |
| 2025-09-17 | ALLO | -0.14 | -6.53 | 13.04 |
| 2025-09-18 | ALLO | -0.14 | -6.53 | 13.04 |
| 2025-09-19 | ALLO | -0.07 | -6.53 | 13.04 |
| 2025-09-22 | ALLO | -0.07 | -6.53 | 13.04 |
| 2025-09-23 | ALLO | -0.07 | -6.53 | 13.04 |
| 2025-09-24 | ALLO | -0.07 | -6.53 | 13.04 |
| 2025-09-25 | ALLO | -0.07 | -6.53 | 13.26 |
| 2025-09-26 | ALLO | -0.07 | -6.53 | 13.26 |
| 2025-09-29 | ALLO | -0.07 | -6.53 | 13.26 |
| 2025-09-30 | ALLO | -0.07 | -6.53 | 13.26 |
| 2025-10-01 | ALLO | -0.07 | -6.53 | 13.26 |
| 2025-10-02 | ALLO | -0.07 | -6.53 | 13.26 |
| 2025-10-03 | ALLO | -0.07 | -6.53 | 13.26 |
| 2025-10-06 | ALLO | -0.07 | -4.91 | 13.26 |
| 2025-10-07 | ALLO | -0.07 | -4.91 | 13.26 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.23
Avg. EPS Est. Current Quarter
-0.23
Avg. EPS Est. Next Quarter
-0.21
Insider Transactions
-0.07
Institutional Transactions
-4.91
Beta
0.41
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
22
Sentiment Score
52
Actual DrawDown %
97
Max Drawdown 5-Year %
-97.8
Target Price
7.51
P/E
Forward P/E
PEG
P/S
P/B
0.86
P/Free Cash Flow
EPS
-1.11
Average EPS Est. Cur. Y
-1.02
EPS Next Y. (Est.)
-0.98
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.59
Return on Equity vs Sector %
-93.9
Return on Equity vs Industry %
-80.3
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
Allogene Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading